Furthermore, the precise mechanisms driving lung cancer initiation and progression, chemotherapeutic resistance, and resistance to targeted therapies such as those against Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK), as well as immune resistance, remain areas necessitating further investigation. Here, ALK is linked to lung cancer.